Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Idiopathic Membranous Nephropathy
67%
M-type Phospholipase A2 Receptor
65%
Nonalcoholic Steatohepatitis
49%
Phospholipase A2 Receptor (PLA2R)
49%
Hepatocellular Carcinoma
39%
Portal Hypertension
38%
Liver Transplant Recipients
38%
High-fat Diet
36%
Antiviral Treatment
36%
Rat Model
35%
Overexpression
33%
Clear Cell Renal Cell Carcinoma (ccRCC)
32%
Clinical Response
32%
Serum Levels
32%
Chronic Antibody-mediated Rejection
32%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
32%
Sustained Virological Response
32%
Chronic Hepatitis C
32%
Tacrolimus
32%
Diagnostic Value
32%
Focal Segmental Glomerulosclerosis
31%
Liver
29%
Advanced Liver Disease
28%
Liver Biopsy
27%
Predictive Value
26%
Differential Diagnosis
26%
Pancreatic Ductal Adenocarcinoma
23%
Kidney
23%
Nephrotic Syndrome
22%
Corticosteroids
22%
Donor-specific Antibodies
21%
Remission
21%
Membranous Nephropathy
21%
Liver Transplantation
20%
High Glucose
19%
Hepatitis C Virus Genotypes
19%
Treatment Response
19%
Circulating Levels
19%
Tubular Injury
19%
Autoimmune Hepatitis
19%
Obese Patients
19%
Type 2 Diabetes Mellitus (T2DM)
19%
Pathological Findings
19%
Triglyceride Level
19%
Liver Fibrosis
19%
Interleukin-6
18%
Novel Mechanism
18%
Histology
18%
Prognostic Value
17%
Medicine and Dentistry
Nonalcoholic Fatty Liver
93%
Biopsy Technique
70%
Neoplasm
46%
Membranous Glomerulonephritis
41%
Diagnosis
40%
Hepatitis C
38%
Antiviral Therapy
35%
Phospholipase A2 Receptor
32%
Focal Segmental Glomerulosclerosis
32%
Clear Cell Renal Cell Carcinoma
32%
Antibody Mediated Rejection
32%
Liver Graft
32%
Liver Transplantation
32%
Urokinase Receptor
32%
Portal Hypertension
32%
Fibrosis
25%
Liver Disease
25%
Infection
24%
Pancreas Adenocarcinoma
23%
Hepatitis C Virus
23%
Non-Alcoholic Fatty Liver Disease
23%
Hepatocellular Carcinoma
23%
Metabolic Syndrome
21%
Differential Diagnosis
21%
Prevalence
21%
Antibodies
21%
High Fat Food
21%
Overall Survival
21%
Recurrent Disease
20%
Nephrotic Syndrome
20%
Disease Exacerbation
20%
Carcinogenesis
19%
Treatment Response
19%
Autoimmune Hepatitis
19%
Triacylglycerol
19%
Interleukin 6
19%
Liver Metastasis
18%
Allograft
18%
Maturity Onset Diabetes of the Young
18%
Signal Transduction
18%
Liver Fibrosis
18%
Immunoglobulin G4
18%
Outpatient
17%
Kidney Function
17%
Renal Biopsy
17%
Biological Marker
16%
Kidney Transplantation
16%
Pathologist
16%
Acetic Acid Derivative
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
76%
Membranous Glomerulonephritis
57%
Phospholipase A2 Receptor
49%
Liver Cell Carcinoma
49%
Remission
39%
Portal Hypertension
38%
Antivirus Agent
37%
Recurrent Disease
37%
Rat Model
34%
Hepatitis C
32%
Focal Glomerulosclerosis
32%
Urokinase Receptor
32%
Hepatitis C Virus
27%
Infection
24%
Nephrotic Syndrome
23%
Receptor
19%
Liver Disease
18%
Non Insulin Dependent Diabetes Mellitus
18%
Liver Fibrosis
18%
Carcinogenesis
17%
Disease Exacerbation
17%
Ambrisentan
16%
Triacylglycerol
16%
Immunoglobulin G4
16%
Acetic Acid Derivative
16%
Multiple Sclerosis
16%
Chronic Hepatitis B
16%
Hepatitis B(e) Antigen
16%
Autoimmune Hepatitis
16%
Synapsin I
16%
Pancreas Cancer
16%
Endotoxin
16%
Atorvastatin
16%
Hepatitis E Virus
16%
Thrombotic Thrombocytopenic Purpura
16%
Hepatitis E
16%
Liver Metastasis
16%
Acute Hepatitis
16%
Clinical Feature
16%
Hemophagocytic Syndrome
16%
Calpain
16%
Ribavirin
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Intestine Flora
16%
Pancreas Adenocarcinoma
16%
Hepatitis B Virus
16%
Ciclosporin
16%
Tacrolimus
16%
Carboxylase
16%
Sex Hormone Binding Globulin
16%
